SLC3A2 and breast cancer: To further investigate whether SLC7A5/SLC3A2 co-expression affects the response of ER+ breast cancer cells to tamoxifen, we knocked down SLC7A5 and SLC3A2 in combinations in MCF7 and MDA-MB-175-VII cells using siRNAs.